Lantheus Holdings, Inc. (Lantheus) operates as a radiopharmaceutical-focused company.
The company is enabling clinicians to Find, Fight, and Follow disease, to deliver better patient outcomes. The company classifies its products into three product c…
Analysis
Middle-of-the-road
Lantheus Holdings, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is fair. The owner-earnings multiple stands at 20.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 11%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 16/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202381
83
2023202420252026
All-time high
92
Jan 2025
All-time low
62
Mar 2026
Average rank
78
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
56
50
52
61
Price/Earnings
25
69
86
23
Price/Book
28
33
24
45
Dividend Yield
1
1
1
1
Value (overall)
17
46
55
45
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.